LAURUSLABS · Healthcare
The board meets on 29 Oct 2026 to approve the results. This page fills in when the numbers are filed.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,224 cr | ₹1,195 cr | ₹1,440 cr | ₹1,195 cr | ₹1,224 cr | ₹1,415 cr | ₹1,720 cr | ₹1,570 cr | ₹1,653 cr | ₹1,778 cr | ₹1,812 cr | ₹2,026 cr |
| YoY | — | — | — | +1% | 0% | +18% | +19% | +31% | +35% | +26% | +5% | +29% |
| EBITDA margin | 15.4% | 15.1% | 16.7% | 14.3% | 14.5% | 20.1% | 24.5% | 24.3% | 24.4% | 27.0% | 28.3% | 31.5% |
| Other income, % of PBT | 4% | 6% | 18% | 17% | 22% | 7% | 19% | 4% | 10% | 2% | 3% | 2% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 27% | 27% | 30% | 34% | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% |
| Net profit | ₹37.0 cr | ₹23.0 cr | ₹75.0 cr | ₹13.0 cr | ₹20.0 cr | ₹93.0 cr | ₹233 cr | ₹162 cr | ₹194 cr | ₹252 cr | ₹282 cr | ₹362 cr |
| YoY | — | — | — | −52% | −46% | +304% | +211% | +1,146% | +870% | +171% | +21% | +123% |
| Core profit YoY | — | — | — | −59% | −65% | +270% | +188% | +1,327% | +1,250% | +163% | +38% | +121% |
| EPS | ₹0.69 | ₹0.43 | ₹1.40 | ₹0.23 | ₹0.37 | ₹1.71 | ₹4.33 | ₹3.02 | ₹3.61 | ₹4.66 | ₹5.17 | ₹6.80 |
| Flags | · | · | · | ✓ | ✓ | 1 | 1 | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.